ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Simvastatin

Also written as “simvastatin”, “ezetimibe (+) simvastatin” and “Fenofibrate/Simvastatin”.

Its studies are mostly in Hypercholesterolemia · Diabetes Mellitus, Type 2 · Hyperlipidemias · Cardiovascular Diseases · Hypertension, led by 11 companies.

Drug pageSimvastatin: every studyMany companies study it; this page follows only the 65 they lead. All 370 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 7, 200565 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organon290 open or runningphase 4since Sep 7, 2005Sep 21, 2004none ahead
Abbottits history only80 open or runningphase 3since Mar 25, 2004Mar 25, 2004none ahead
Eli Lillyits history only60 open or runningphase 2since Apr 15, 2010Apr 15, 2010none ahead
GlaxoSmithKlineits history only60 open or runningphase 3since Oct 28, 2005Oct 28, 2005none ahead
Merckits history only60 open or runningphase 3since May 24, 2007May 24, 2007none ahead
Pfizerits history only40 open or runningphase 4since Sep 8, 2005Sep 8, 2005none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Jul 21, 2010Jul 21, 2010none ahead
Biogenits history only10 open or runningphase 4since Jun 25, 2007Jun 25, 2007none ahead
Entero Therapeuticsits history only10 open or runningearly phase 1since Oct 3, 2016Oct 3, 2016none ahead
Medtronicits history only10 open or runningearly phase 1since Jul 21, 2008Jul 21, 2008none ahead

Also a collaborator on its studies: Immunogenics, Regeneron Pharmaceuticals, Celerion and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Organon only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Sep 21, 2004.

  1. Dec 8, 20062 phase 3 studies in HypercholesterolemiaNCT00409773, NCT00413972
  2. Jan 17, 2007Phase 4 study in HypercholesterolemiaNCT00423579 · 120 enrolled
  3. Feb 28, 2007Phase 4 study in HypercholesterolemiaNCT00442897 · 229 enrolled
  4. Apr 18, 2007Phase 3 study in HypercholesterolemiaNCT00462748 · 786 enrolled
  5. May 24, 2007Phase 3 study in HypercholesterolemiaNCT00479713 · 618 enrolled
  6. Jul 2, 2007Phase 3 study in HypercholesterolemiaNCT00496730 · 256 enrolled
  7. Oct 29, 2007Phase 3 study in Coronary DiseaseNCT00551447 · 616 enrolled
  8. Mar 31, 20084 phase 3 studiesNCT00652301, NCT00651560, NCT00651391 and 1 more
  9. Mar 31, 2008Phase 4 study in HypercholesterolemiaNCT00650663 · 247 enrolled
  10. Apr 1, 20082 phase 4 studies in HypercholesterolemiaNCT00653835, NCT00654628
  11. Apr 1, 2008Phase 3 study in HypercholesterolemiaNCT00653523 · 151 enrolled
  12. Aug 19, 2008Phase 4 study in Lupus Erythematosus, SystemicNCT00739050 · 4 enrolled
  13. Mar 12, 2009Phase 3 study in Cardiovascular DiseasesNCT00862251 · 808 enrolled
  14. Mar 6, 2019Phase 3 study in Hyperlipoproteinemia Type IINCT03884452 · 50 enrolled

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
AtorvastatinruleViatrisphase 4186
rosuvastatinruleAstraZenecaphase 4184
pitavastatinruleKowaphase 436

Studies

All 29 Organon leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03884452Hyperlipoproteinemia Type II3CompletedMay 24, 200150
NCT00862251Cardiovascular Diseases3CompletedMar 2011808
NCT00739050Lupus Erythematosus, Systemic4TerminatedFeb 1, 20084
NCT00654628Hypercholesterolemia4CompletedJul 1, 2009173
NCT00653835Hypercholesterolemia4CompletedAug 1, 2004153
NCT00653523Hypercholesterolemia3CompletedJun 1, 2009151
NCT00652301Cholesterol3CompletedApr 200440
NCT00651560Hyperlipidemias3CompletedDec 23, 2005167
NCT00651391Hypercholesterolemia3TerminatedSep 1, 200428
NCT00650819Hypercholesterolemia3CompletedFeb 1, 2005240
NCT00650663Hypercholesterolemia4CompletedSep 1, 2004247
NCT00551447Coronary Disease3CompletedMar 2003616
NCT00496730Hypercholesterolemia3CompletedAug 2008256
NCT00479713Hypercholesterolemia3CompletedMar 1, 2008618
NCT00462748Hypercholesterolemia3CompletedJun 2008786
NCT00442897Hypercholesterolemia4CompletedOct 2008229
NCT00423579Hypercholesterolemia4CompletedMar 1, 2008120
NCT00413972Hypercholesterolemia3CompletedNov 2006392
NCT00409773Hypercholesterolemia3CompletedJul 20081,143
NCT00398294Hypercholesterolemia · Taiwan4CompletedApr 4, 200630
NCT00389896HDL Cholesterol3CompletedOct 4, 2002150
NCT00271817Hypercholesterolemia3CompletedFeb 20081,220
NCT00166530Atherosclerosis4CompletedFeb 2007367
NCT00166504Hypercholesterolemia4CompletedOct 2007203
NCT00157924Hypercholesterolemia4CompletedSep 2007190
NCT00129402Hypercholesterolemia3CompletedJun 2007248
NCT00132717Hypercholesterolemia3CompletedJun 1, 2007450
NCT00093899Hyperlipidemias3CompletedSep 2005611
NCT00092157Hypercholesterolemia3CompletedMar 3, 2003571

How it is read

Names in the registry

  • “Simvastatin”, 44 entries
  • “simvastatin”, 14 entries
  • “ezetimibe (+) simvastatin”, 9 entries
  • “Fenofibrate/Simvastatin”, 5 entries
  • “Ezetimibe + Simvastatin”, 4 entries

Codes read as this program: MK0733.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.